Report Keyword:

China Biological Medicine Outsourcing Industry Indepth Research and Investment Strategy Planning Report, 2013-2017

China Biological Medicine Outsourcing Industry Indepth Research and Investment Strategy Planning Report, 2013-2017

Last Update:2014-04-29

Form of services:Book + (pdf or doc file) + CD

Send method:EMS 2-3 days for delivery

English Service:+86 0755 33220413

Chinese Service:+86 800-8306390 800-8306395

Report price:$7900   Print: $7800   CD: $7800

Online Consultation
Special statement:
Recently we find there are some sites steal report contents from who put those contents on their sites for sale by making a little changes about the contents or remaining the same which deceives buyers(e.g. unable to get full or correct reports, or main body differs from contents that announced on sites).Therefore, we recommend paying a visit to Qianzhan personally or by your friends, and make payment after confirmation. Special statement: Qianzhan is the only and right holder of all the research reports, and has never used a third party to sell any reports, please be aware of the trademark " " when purchasing. Qianzhan is the largest and strongest consultancy, who owns the greatest number of researchers. Here followed "Nine standards of companies' identificatios"。

This table of content is original, without written permission of Qianzhan, any unit or individual shall not use, copy, or transfer the reports.


Table of Content

Since the 21st century, input of western medicine is increasing while new drug varieties are decreasing. Thus the outsourcing is a perfect choice for pharmaceuticals giants.

Outsourcing is a general trend. According to the statistics of British Antisoma, 35% of pharmaceutical companies in the current world choose outsourcing. At present, annul growth of global pharmaceutical R&D outsourcing market is 20% to 25%. There is about 3.05 billion USD R&D business of global pharmaceutical companies outsourcing to the independent third party laboratory in 2009, while it reaches 3.6 billion USD in 2010.

For China market, the medium-small size corporations lack of technology and talent reserve; not all the corporations can afford for the cost of new drug R&D. Thus, it is better for them to develop circuitously rather than scrambling the business along in the world. Choosing the R&D outsourcing service for big corporations is a practical development bridge links the short-term efficiency and long-term strategy for the corporations who are interested in new drug R&D.

For the newly pharmaceutical market outsourcing service, China is one of the fast development countries. Currently, among the thousands of biological medicine outsourcing service corporations, the leading corporations are WuXi AppTec, Shanghai ChemPartner Co. Ltd. (ChemPartner), CharlesRiver and Fountain Medical Development Ltd. (FMD) and so on. The outsourcing service scale reaches 4 billion USD and the annul growth is 25%.

Presently, pharmaceutical outsourcing service is regarded as an important item for local development and productbility service industry and new growth dot in economic development by Beijing, Shanghai and Tianjin, etc. Advantages for Beijing focus on the fields of drug non-clinical trials and drug clinical trials, drug metabolism studies and so on, while for Shanghai it focuses on chemical synthesis, drug non-clinical trials and clinical trials.

Meanwhile, along with the gradual perfection of Chinese medicine policy, profound changes are taking place in new drug R&D structure—transfer from the copy model to innovation drug R&D with independent intellectual property. Besides, capable R&D business develops from pharmaceuticals synthesis, active ingredients production and clinical trials to pharmaceuticals synthesis, pharmacokinetics, drug safety evaluation and phase III clinical, etc. All these promote rapid rise of China CRO. Even though there are only 5 outsourcing companies which is capable to provide one-stop-solution covering new drug R&D service, China CRO market scale has reached 17 billion Yuan in 2010. And CRO companies with output value exceed 10 million Yuan has been more than 15. China has surpassed India and become the first choice R&D outsourcing country in Asia.

With the improvement of China intellectual property environment, more and more Euro-American large-scale corporations choose Chinese corporations as outsourcing partners. There are more than 400 pharmaceutical R&D outsourcing corporations in nationwide and most of them locate in Beijing Zhongguancun, Chengdu Hi-tech Park and Shanghai Zhangjiang Hi-tech Park, etc. They are engaged in R&D outsourcing segmentations like compounds, raw material medicine research, medicine preclinical research and clinical trials and so on.

Nowadays market scale of China CRO is not large. But it attracts investment capital due to the industry characters of “high added value and high profit rate”.

In March, 2011, the Shanghai Medicilon Inc., which is specialized in integrated services, attracts Fortune Capital as a strategy investment partner and is hopeful to be on the GEM in 3 years. At the same time, many domestic CRO corporations, like Hangzhou Tigermed Consulting Co., Ltd and Shanghai Medicilon Inc. has started their IPO plans. China pharmaceutical outsourcing market shows enormous investment potential according to huge disease resources and medical market as well as good clinical conditions.

In the following years, growth rate of Euro-American market will decrease while Asian newly market will grow to 11%-14%. It brings a great development opportunity to Asian countries. As the strongest competitor for China, India has taken steps to promote the development of pharmaceutical outsourcing market and regards it as an “inevitable strategy”. China should have a fast react, like forming strategy alliance, fastening construction of supporting infrastructure and R&D base and founding industry institutes, to integrate various technical advantages and make core competition.

In addition, from the growth experience of foreign large-scale pharmaceutical outsourcing corporation, provide “all-around service” is the key for outsourcing. For China pharmaceutical outsourcing corporations, synthesizing outsourcing of one-stop-solution R&D service is much important than well serving the transnational pharmaceutical companies. Under such model, resource assembly effect will reaches its peak. At present, China new drug GMP is under its promotion. Such a fresh new outsourcing model will definitely bring unprecedented opportunities for domestic corporations which are long for new products. What’s more, it will become the mainstream model for China pharmaceutical outsourcing in the future.


Qianzhan Business Information Co., Ltd. Industry Research Center
Research Team of Biological Medicine Outsourcing Industry

China Biological Medicine Outsourcing Industry Report" related reports »

Purchase Mode:

1. English Service:  +86 0755 33220413

2. Chinese Service:  +86 8008306390 8008306395

3. Mail Order:

4. Online Order:  Click "Order Now" button on this page

5. Purchase On-site:  19F Block A, First World Plaza, Hongli West Rd, Futian District, Shenzhen China

Warm tips:
  • 1. Please be aware of " Qianzhan " trademark, qianzhan has never used any third to sell reports, please make a phone call and purchase it directly.
  • 2. You are warmly welcome to visit Qianzhan, and close transaction after confirmation.
Industry Research
·Energy and Environment»
New Energy Natural Gas Energy Conservation Water Resources Coal Electricity Others
·Recreation and Sports»
Education Advertisement Film and Television Publication Packing and Printing Sports Resort Hotel Catering Internet Animation Others Media
·Financial Services»
Banking Insurance Securities Leasing Credit Others
·Transport Logistics and Supporting»
Water Transport Airport Road Transport Logistic Distribution Vehicle and Fittings Post-Market Others
·Medical and Health»
Medical Device Biomedicine Medical Institution Healthcare and Nursing Medicine and Pharmacy Others
·Retail or FMCG»
Retail Commercial Trade Food Beverage Dairy Product Seasoning Wine and Tobacco Cosmetics Cleaning Product Daily Necessities Others
·Real Estate and Construction»
Real Estate Real Estate Intermediary Public Safety Construction Engineering Survey and Design Building Materials Housing Accomodation Others
·Mechanical Manufacturing»
Precision Instrument Transport Instrument Electricity Supporting Equipment Special Equipment General Equipment Others
·New Chemical Material»
Ink and Pigment Coating Chemical Fibres Synthetic Fibres Chemicals Industrial Chemicals Rubber Plastics Basic Chemicals Others
·Light Textile and Clothing»
Luxury Jewelry Leather Raw Materials Shoes and Hats Clothing Textile Others
·Household Appliance and IT»
White Goods Optic Instrument Electrical Component Semiconductor Brown Goods Small Appliances Communication IT Consumer Electronics Others
·Minerals and Metallurgy»
Metal Product Metallurgy Non-Ferrous Metal Steel Mining Industry Others
Copyright Notice

1. The copyright of this report is reserved by Qianzhan Business Information Co., Ltd. (Industry Research Institute of Qianzhan), the shipment and post-sale service is handled by the issue department of Qianzhan Business Information Co., Ltd. (Industry Research Institute of Qianzhan). The only copyright of all research report products of our company is reserved; we did not authorize any third party sales agent, if you are to purchase our report, please contact our customer service directly.

2. A limited of customers are offered with our reports with compensation; those reports are only for internal usage and are only for researching and analyzing purposes. We will not be responsible for any misunderstanding or legal issues caused by external usage or references with the report.

Beginner's Guide
Order Reference
Delivery & Payment
Sale protection
Service Hotline
  • Order Hotline:+86 800-830-6390
  • Customer service:
    +86 800-830-6395
    +86 400-068-7188